Articles tagged with Blood Cancer
Researchers found a simple combination of two blood tests can diagnose myeloma in GPs, enabling earlier diagnosis and treatment. The study analyzed over 2,700 cases and suggested integrating a system to alert clinicians to relevant symptoms or changes in blood parameters.
Researchers developed QPOP, a computational platform that identifies effective drug combinations against bortezomib-resistant MM. The platform successfully predicted dosages for combination therapies, leading to reduced tumor size and prolonged survival in mouse models.
Research found that invisible stool blood is associated with a heightened risk of death from bowel cancer, as well as circulatory, respiratory, digestive, and hormone diseases. A positive faecal occult blood test result was linked to an 8-fold increased risk of bowel cancer mortality.
A new technique detects mutations that affect large chunks of chromosomes in people with clonal hematopoiesis, a condition associated with substantially increased blood cancer risk. The study identified specific events that drive this increase in risk and suggests promising directions for future work.
A new report calls for better evaluation of side effects from modern blood cancer treatments, which have dramatically improved survival rates. The Commission proposes new approaches to reporting adverse events, including capturing chronic and cumulative effects.
A new clinical trial analysis found that combining an aromatase inhibitor with ovarian function suppression yields a 10-15% improvement in freedom from distant recurrence for high-risk younger breast cancer patients. Women at low risk saw minimal benefit, while those at intermediate risk gained a 4-5% advantage.
Researchers at Dana-Farber Cancer Institute have developed a blood test that can detect early-stage lung cancer using genome sequencing. The test, which analyzes free-floating DNA in the blood, has shown promise in detecting lung cancer with a low rate of false positives.
Scientists have engineered new anti-cancer antibodies that attract killer T cells directly to cancer cells covered with the ROR1 protein. These bi-specific antibodies can target several types of cancer and work for about five days, outlasting current approaches.
A new diagnostic test developed by researchers at UC San Diego shows promise for detecting pancreatic cancer earlier. The test uses electronic chip-based system to extract exosomes directly from blood, providing results in less than an hour. The findings have the potential to detect cancer early on without invasive surgical procedures.
Researchers found that most oncologists discuss medical marijuana with patients and nearly half recommend it, but only 30% feel knowledgeable enough to make recommendations. The study suggests a discrepancy between attitudes and practices regarding medical marijuana's utility in oncology.
Researchers have identified human-specific cancers that differ from animal counterparts, suggesting potential evolutionary origins. The study reveals cancer patterns in humans vary significantly from those of other species, highlighting the need for further investigation into the evolutionary underpinnings of cancer.
A study published in Circulation found that patients with acute thrombosis in the leg are at a three-fold higher risk of developing cancer during the first six months after the blood clot. The risk is highest for smoking-related forms of cancer, such as lung and pancreatic cancer.
The BIABooster device characterizes DNA in blood circulation with new precision and sensitivity, identifying promising signatures for cancer monitoring. It has been shown to detect DNA up to a concentration of 10 fg/μL with precisions of 20% and 3%.
Researchers at Johns Hopkins Medicine have developed a non-invasive test called UroSEEK, which uses urine samples to detect DNA mutations associated with bladder cancer. The test significantly enhances early detection for patients at risk and surveillance of those who have already been treated. When combined with cytology, the sensitiv...
Researchers at WashU Medicine used CRISPR to engineer human T cells that can attack human T cell cancers without succumbing to friendly fire. The new approach also allows for the use of therapeutic T cells from any healthy donor, eliminating the need for a matched donor or patient's own T cells.
Researchers at UT Southwestern's Simmons Cancer Center have made a historic breakthrough in CAR-T therapy for acute lymphoblastic leukemia (ALL) in children and young adults. Eighty-one percent of patients treated with CAR-T therapy went into remission, offering new hope for those previously untreatable.
Researchers developed CancerSEEK, a noninvasive blood test detecting cancer mutations and protein biomarkers in the blood. The test detected cancer with a sensitivity of 69-98% and was 99% specific.
The CancerSEEK test is a noninvasive, multianalyte test that evaluates levels of eight cancer proteins and the presence of cancer gene mutations in the blood. The test has greater than 99% specificity for cancer and can identify the location of tumors with high accuracy.
A gene enhancer cluster, BENC, plays a crucial role in regulating Myc activity and cancer growth. The discovery suggests BENC as a potential target for novel therapies against blood cancer.
Researchers discover epigenetic supersimilarity in identical twins, influencing biological characteristics and cancer risk. This phenomenon is associated with a relatively small group of genes, but many are linked to several types of cancer.
Dr. Benjamin Ebert has made significant contributions to understanding the genomic landscape of adult myelodysplastic syndromes (MDS) and its impact on both hematologic malignancies and cardiovascular disease. He is also known for his work on precision medicine and his innovative approaches to treating diseases.
Researchers propose a revised cancer staging approach that incorporates liquid biopsy to improve diagnosis and treatment accuracy. The new system has shown promising results in guiding cancer care, particularly in detecting early-stage cancer and tracking treatment response.
Research reveals significant gaps in participation among older adults with blood cancers, underscoring the need to close the gap and increase enrollment. Most patients under 65 are over-represented, while those aged 75+ account for only 4% of trials despite being diagnosed at a higher rate.
A study showed that treating younger patients with a combination of chemotherapy and a molecularly targeted drug significantly improves response over traditional chemotherapy alone. The therapy combination resulted in a complete response rate of 37% compared to 20% historically, with ongoing maintenance showing deepened responses.
Scientists sequenced 186 bone marrow biopsies from patients with smoldering multiple myeloma, identifying mutations more frequent in high-risk patients. The study also found that cell-free DNA sequencing may help monitor patients with myeloma and its precursor conditions.
A new study demonstrates techniques to track genetic changes in multiple myeloma over time using cell-free DNA found in blood. This approach potentially provides a more representative view of the disease throughout the body than traditional bone marrow biopsies.
Preliminary results from a clinical trial of nivolumab indicate effectiveness and significant side effects, prompting further trials in this group. The drug ipilimumab also produced responses in nearly one-third of patients with relapsed hematologic malignancies after an allogeneic stem cell transplant.
Researchers at MD Anderson Cancer Center presented significant advances in patient survival for various blood cancers, including multiple myeloma and mantle cell lymphoma. The studies showed promising results for new treatments, such as combination chemotherapy and targeted therapies.
Research shows adult survivors of childhood cancer were 2.6 times more likely to have hypertension than expected based on age, sex, race, and BMI. The prevalence increased over time, with 70% of survivors having hypertension by age 50.
A study found that African-American patients with multiple myeloma have increased mutations in genes BCL7A, BRWD3 and AUTS2, while white patients have more mutations in TP53 and IRF4. This suggests a different approach may be needed for targeted therapies.
Barbara Savoldo, MD, PhD, received a three-year grant to support research into an investigational CAR T-cell treatment for acute lymphoblastic leukemia with a built-in safety switch. The goal is to adapt an 'off switch' to reduce potentially lethal side effects of immunotherapy treatments.
Researchers have developed a new diagnostic method for early detection of hepatocellular carcinoma, based on a simple blood sample containing circulating tumor DNA. The test has been shown to highly correlate with tumor burden, treatment response, and stage of cancer.
A blood test for human papillomavirus (HPV) may help forecast treatment response in throat cancer patients, according to preliminary findings. Patients with low or undetectable HPV16 levels in the blood had higher risk of persistent or recurrent disease.
A genetic fault in the CDKN2A gene has been linked to reduced effectiveness of leukemia treatment, highlighting the need for personalized treatment approaches. The study, which treated 259 people with AML or MDS, found that those with the mutation survived for 4.5 months on average, compared to 11 months for those without it.
Researchers found melatonin boosts immune response against cancer cells, inhibits growth and protects healthy cells from chemotherapy effects. Timing of melatonin treatments is crucial for their anticancer effects due to its role in regulating circadian rhythms.
A new blood test developed by Johns Hopkins Medicine accurately identifies more than half of people with early-stage colorectal, breast, lung, and ovarian cancers. The test distinguishes between cancer-specific DNA and altered DNA that can be mistaken for biomarkers.
Muller Fabbri's research focuses on targeting immune cells contributing to disease progression in neuroblastoma. He aims to identify new molecular targets to prevent and overcome cancer resistance to treatment.
Researchers at the University of Sheffield have discovered that methotrexate, an arthritis drug, shows promise in treating Polycythemia Vera, a type of blood cancer affecting 3,000 people annually. The treatment has been shown to suppress JAK/STAT pathway activation and normalise blood counts in mice models.
Researchers at Queen Mary University of London have developed a highly accurate blood test that can identify patients with aggressive prostate cancer. The test detects rare cells in the blood, including megakaryocytes, which are strongly linked to patient survival, and 'EMTed' CTCs, associated with poor patient outcomes.
Researchers have identified histologic subtype distinctions and heterogeneity of neurofibromatosis type 1-associated tumors through immune profiling. The findings suggest potential targets for T cell-based immunotherapies, but also highlight the complexity of tumor heterogeneity within subtypes.
A large-scale study found that raised blood platelet counts are a strong predictor of cancer, with lung and colorectal cancers being more commonly diagnosed. The research suggests that substantial numbers of people could have their cancer diagnosed up to three months earlier if thrombocytosis prompted investigation.
Research shows that blood cancer patients are less likely to enroll in hospice care compared to solid cancer patients. However, a survey of hematologic oncologists found that 68% agree that hospice care is helpful for blood cancer patients, and most would refer patients if red blood cell transfusions were available.
Research from Ohio State University found a surprising relationship between blood sugar and brain tumors. While diabetes increases cancer risk at other sites, it lowers the risk of gliomas, the most common type of malignant brain tumor.
Researchers have found that a signaling molecule produced by T-cells can induce the regression of blood vessels in tumors, effectively shutting down their supply of oxygen and nutrients. This discovery could lead to improved treatment options for solid tumors using immunotherapy with T-cells.
TET2 mutations are found in various blood cancers, including myelodysplastic syndrome and acute myeloid leukemia. The enzyme plays a crucial role in controlling gene expression, and its loss allows other genes to mutate, creating conditions for cancer to thrive.
Combining anti-angiogenic and immune-stimulating therapies creates specialized blood vessels that deliver cancer-fighting immune cells to tumors, leading to better therapeutic outcomes. This breakthrough research may improve treatments and prolong survival periods for patients.
Researchers have developed a biomarker that can detect early signs of HPV16 E6 antibody presence in blood samples, indicating high risk of developing oropharyngeal cancer. The test is highly specific but not suitable for larger population groups due to low new case incidence rates.
The Georgia Cancer Center is part of a national effort to study cancer disparities across racial and ethnic groups. Researchers will collect data from 2,400 patients with early-onset cancers to better understand the underlying causes.
Researchers developed a computer program to diagnose cancer and locate tumors in blood samples, with an accuracy rate of 80% for early-stage cancers. The program uses molecular patterns in cancer DNA to identify the type and location of cancer.
Researchers identified a series of proteins in blood plasma that signify cancer presence, offering a promising early detection method. The breakthrough discovery could enable regular blood tests to monitor treatment effectiveness and detect cancer recurrence.
A new compound has been found to reverse the allegiance of innate immune system cells, turning them from tumor enablers into tumor opponents. When combined with chemotherapy or another immunotherapy, it significantly extended the period of tumor remission.
Researchers have developed a new blood test that can detect cancer and identify its location in the body, offering an alternative to invasive surgical procedures. The test works by analyzing DNA released by dying tumor cells and identifying specific methylation patterns unique to each tissue type.
Researchers found several gene variants near ABCB4 and ABCB1 genes that may predispose individuals to gallbladder cancer. These variants could lead to better understanding of the disease causes and potentially develop new treatments.
Researchers discovered genetic mutations in TP53, RAS pathway genes, and JAK2 gene associated with shorter survival and increased relapse risk after stem cell transplant. The findings provide a guide for identifying patients most likely to benefit from a transplant, enabling personalized treatment strategies.
A blood test detecting hypermethylation in tumor DNA predicts shorter survival for women with high levels of cancer-linked DNA, indicating worsening disease. The test, cMethDNA, may help identify breast cancers at higher risk for recurrence and track treatment success.
A phase 1 clinical trial has demonstrated the safety and effectiveness of a combination of two targeted agents, ibrutinib and TGR-1202, in treating relapsed or hard-to-treat chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The regimen showed promising results, with one patient achieving complete remission.
Researchers from Dana-Farber Cancer Institute found that an immunotherapy-based drug combination can prevent progression of high-risk 'smoldering' multiple myeloma, causing tumor shrinkage in 82.6% of patients. The treatment was well-tolerated with low toxicities and resulted in remission for many patients.
A study from Dana-Farber Cancer Institute found that 30% of lymphoma patients with autologous transplants carry genetic mutations increasing their risk of developing second blood cancers and dying from other causes. The most commonly mutated gene was PPM1D, associated with an abnormal condition called CHIP.
Researchers at Dana-Farber Cancer Institute have found that an immunotherapy drug called nivolumab can induce lasting remissions in patients with recurrent or refractory primary central nervous system lymphoma and primary testicular lymphoma. Four out of five patients treated with the drug showed a complete response to treatment.
Researchers found that oral vancomycin prevented C. diff in 73% of patients undergoing stem cell transplants, compared to 20% in those without the medication. The study suggests a potential new standard of care for transplant patients, but further study is needed due to rising antibiotic resistance.